

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934

**PlasmaTech Biopharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware** **83-0221517**  
(State of incorporation or organization) (I.R.S. Employer Identification No.)

**4848 Lemmon Avenue, Suite 517, Dallas, Texas** **75219**  
(Address of principal executive offices) (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered	Name of each exchange on which each class is to be registered
<u>Common Stock, \$0.01 par value per share</u>	<u>The NASDAQ Stock Market LLC</u>
<u>Warrants to purchase Common Stock</u>	<u>The NASDAQ Stock Market LLC</u>

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

Securities Act registration statement file number to which this form relates: **333-197220** (if applicable).

Securities to be registered pursuant to Section 12(g) of the Act:

**None**  
(Title of class)

---

## INFORMATION REQUIRED IN REGISTRATION STATEMENT

### Item 1. Description of Registrant's Securities to be Registered.

A description of the securities of PlasmaTech Biopharmaceuticals, Inc., a Delaware corporation (the "Registrant"), to be registered hereunder is set forth under the heading "Description of Securities" in the prospectus included in the Registrant's Registration Statement on Form S-1 (File No. 333-197220), initially filed with the Securities and Exchange Commission (the "Commission") on July 2, 2014, as subsequently amended (the "Registration Statement"), and in a prospectus to be subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the Registration Statement, which prospectus shall be deemed to be incorporated herein by reference.

### Item 2. Exhibits.

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on the NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Exchange Act.

## SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

PLASMATECH BIOPHARMACEUTICALS, INC.

Date: November 4, 2014

By: /s/ Harrison Wehner

Harrison Wehner

President and Chief Financial Officer

---